Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 5/20 | 0.57 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | GSK3A | P49840 | 2/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | PNP | P00491 | 1/20 | 0.50 |
| ▸ | KRAS | P01116 | 1/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29973359 | 0.93 | HINT1 (0.55) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL29479255 | 0.90 | HPGD (0.54) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL26276132 | 0.90 | HPGD (0.54) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL25387704 | 0.90 | HPGD (0.54) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL19590179 | 0.90 | HPGD (0.54) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL25402409 | 0.90 | HPGD (0.54) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL25070741 | 0.89 | HINT1 (0.59) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL22326750 | 0.89 | NT5E (0.54) | HINT1NT5ETGM2KRASTAS1R3 | |
| SCHEMBL22326762 | 0.88 | NT5E (0.54) | HINT1NT5ETGM2KRASTAS1R3 | |
| SCHEMBL24686969 | 0.88 | HPGD (0.52) | HINT1NT5EHPGDGSK3ARPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059729-A1 | MULTIFUNCTIONAL CYCLIC DINUCLEOTIDE AND USE THEREOF | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) | 2024-02-22 | — | — | US | disclosed |
| EP-4242218-A1 | MULTIFUNCTIONAL CYCLIC DINUCLEOTIDE AND USE THEREOF | Tyligand Bioscience (Shanghai) Limited (CN) | 2023-09-13 | — | — | EP | disclosed |
| WO-2022083584-A1 | MULTIFUNCTIONAL CYCLIC DINUCLEOTIDE AND USE THEREOF | 泰励生物科技（上海）有限公司 | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059729-A1 | MULTIFUNCTIONAL CYCLIC DINUCLEOTIDE AND USE THEREOF | MAVS, IRF3, STING1 | HINT1 1480/4885NT5E 389/4885HPGD 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.